<- Go Home

Insmed Incorporated

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Market Cap

$11.7B

Volume

2.2M

Cash and Equivalents

$461.5M

EBITDA

-$695.1M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$264.9M

Profit Margin

77.25%

52 Week High

$80.53

52 Week Low

$21.92

Dividend

N/A

Price / Book Value

24.14

Price / Earnings

-11.73

Price / Tangible Book Value

36.87

Enterprise Value

$11.4B

Enterprise Value / EBITDA

-17.32

Operating Income

-$703.9M

Return on Equity

890.75%

Return on Assets

-26.05

Cash and Short Term Investments

$1.5B

Debt

$1.2B

Equity

$483.4M

Revenue

$343.0M

Unlevered FCF

-$333.7M

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches